A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

ConclusionsPeptide vaccine administered in the adjuvant breast cancer setting was safe and feasible. The TLR3 adjuvant, poly-ICLC, plus helper peptide mixture provided modest immune stimulation. Further optimization is required for this multi-peptide vaccine/adjuvant combination.Trial registrationClinicalTrials.gov(posted 2/15/2012): NCT01532960. Registered 2/8/2012.https://clinicaltrials.gov/show/NCT01532960
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research